Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30607215 | 1.00 | MEN1 (0.32) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL5514290 | 0.94 | HSD17B10 (0.34) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL5514321 | 0.91 | APP (0.31) | APP | |
| SCHEMBL7979895 | 0.88 | HSD17B10 (0.34) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL15935764 | 0.81 | RAPGEF4 (0.34) | TSHR | |
| SCHEMBL25153460 | 0.79 | GRM4 (0.36) | MEN1TSHRMAPK1KMT2A | |
| SCHEMBL20177766 | 0.79 | KDM1A (0.35) | MEN1TSHRKMT2A | |
| SCHEMBL5514141 | 0.79 | ALDH1A1 (0.36) | — | |
| SCHEMBL5514216 | 0.79 | RET (0.39) | CA12CA1CA2CA9APP | |
| SCHEMBL25177509 | 0.79 | NPC1 (0.35) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853741-B | Preparation method of novel coronavirus main protease inhibitor | 苏州立新制药有限公司 | 2023-08-04 | — | — | CN | claimed |
| CN-116640140-A | Polycyclic-carbamoyl pyridone compounds and pharmaceutical uses thereof | 吉利德科学公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-114853741-B | Preparation method of novel coronavirus main protease inhibitor | 苏州立新制药有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| CN-111303152-B | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | 吉利德科学公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| CN-113527262-B | Refining method of delafloxacin and meglumine salt thereof | 安徽普利药业有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-113527262-A | Refining method of delafloxacin and meglumine salt thereof | 安徽普利药业有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3889156-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020151756-A1 | STABLE SOLID DISPERSIONS OF B-RAF KINASE DIMER INHIBITOR, METHODS OF PREPARATION, AND USES THEREFOR | BEIGENE, LTD. (KY) | 2020-07-30 | — | — | WO | disclosed |
| EP-2927214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-9061008-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140343037-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20130137686-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. | 2013-05-30 | — | — | US | disclosed |
| US-8309548-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110183977-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| CN-102060732-A | 5-amino-4-hydroxy-N-aryl azelamide derivatives as well as preparation methods and medical applications thereof | JIANGSU HENGRUI MEDICINE CO | 2011-05-18 | — | — | CN | disclosed |
| US-7906529-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7358370-B2 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | SERENEX, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| EP-0415585-A1 | Fluorobenzene derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137686-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | MEN1 3035/4885ALOX15 1503/4885TSHR 1413/4885 |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | MEN1 966/4885ALOX15 781/4885TSHR 3400/4885 |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | MEN1 966/4885ALOX15 781/4885TSHR 3400/4885 |
| US-20140343037-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | MEN1 3035/4885ALOX15 1503/4885TSHR 1413/4885 |
| US-20110183977-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | MEN1 3035/4885ALOX15 1503/4885TSHR 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.